All In Biotech

Drug Trial Radar · NCT00158691

Intravenous Versus Subcutaneous Amifostine in Prevention of Xerostomia After RT for Head and Neck Carcinomas

A Randomized Phase III Study Comparing Intravenous Versus Subcutaneous Administration of Amifostine in Prevention of Xerostomia for Patients Receiving Radiotherapy for Head and Neck Carcinomas

Last checked: Nov 20, 2026Latest source record: Sep 12, 2005 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 296 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

296

Actual

Start

Mar 2001

Primary completion

Not stated

Sponsor

Lead sponsor
Groupe Oncologie Radiotherapie Tete et CouAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Schering-Plough
First posted
Sep 12, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years

Summary

As written by the sponsor on the registry.

Prospective randomized study in order to compare intravenous versus subcutaneous administration of amifostine in patients receiving radiotherapy for head and neck cancer. Salivary flow will be evaluated during few years after the treatment by a clinical evaluation, the measure of the weight of saliva and a patient benefit questionnaire cotation.

Conditions

  • Head and Neck Cancer

Interventions

  • EthyolDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Late xerostomia rate

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Centre Régional de Lutte contre le Cancer de Nantes-Atlantique

    Nantes, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.